Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (6228)	1/20/2000 5:39:00 PM
From: Bill Wexler	Read Replies (5) \| Respond to of 10293

As soon as GUMM demonstrates that its claims are true and I see actual earnings on the bottom line, I will be happy to cover my short position and admit publicly that I was wrong. So far, there is zero published scientific evidence that Zicam helps shorten the duration of common colds and GUMM has not produced any positive earnings. Stock touts for scientific frauds tend to believe that a rising stock price validates their claims. Zonagen (ZONA) touts believed the same thing while I was shorting their stock over a 2 year period from 15 a share to 40. The stock currently trades at 6 (where it remains grossly overvalued). The only thing that a rising stock price proves is that there's a great deal of stock speculation by scientific illiterates. Without earnings, the price is doomed to collapse, and the vast majority of the speculators will lose money. March 18, 1998 Message 3754891 finance.yahoo.com